Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2024-12-04 Declaration of Voting R…
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital social" (Information relative to the total number of voting rights and shares comprising the share capital). It explicitly references Article L233-8-II of the French Commercial Code and Article 223-16 of the AMF General Regulation. It provides a table detailing the number of outstanding shares and total voting rights as of November 30, 2024. This type of mandatory periodic disclosure in France, focusing specifically on the total share capital and voting rights, is typically classified as a regulatory filing or a specific capital structure update. Given the options, it most closely aligns with a notification regarding capital structure changes or a general regulatory filing. Since it is a specific, recurring disclosure about the total number of shares and voting rights, it fits best under 'Share Issue/Capital Change' (SHA) if it reflects a change, or 'Regulatory Filings' (RNS) if it's a standard monthly update not covered elsewhere. Because the core content is the calculation and reporting of the total number of shares and voting rights, which is a fundamental aspect of capital structure reporting, SHA is a strong candidate. However, the structure strongly suggests a mandatory regulatory disclosure required by the AMF, which often falls under RNS if a more specific code like SHA (which usually implies an issuance/buyback event) isn't perfectly matched. Given the context of French regulatory reporting for capital structure updates, and the lack of a specific 'Voting Rights Disclosure' code, RNS (Regulatory Filings) serves as the most appropriate general category for this mandatory AMF disclosure, although SHA is related. I will select RNS as the general regulatory disclosure fallback for this specific type of mandatory capital structure notification not explicitly listed elsewhere.
2024-12-04 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Monthly information regarding the total number of voting rights and shares comprising the share capital" and references French regulatory articles (Commercial Code, AMF General Regulations). It provides a table detailing the number of shares and voting rights as of November 30, 2024. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory requirement, often related to major shareholding notifications or capital structure updates. Since it explicitly details the total number of shares and voting rights, it most closely aligns with notifications regarding capital structure changes or significant ownership thresholds. Given the options, 'Major Shareholding Notification' (MRQ) is the closest fit for regular updates on the total number of shares/rights, although 'Share Issue/Capital Change' (SHA) is also related. However, the content is a standard monthly disclosure of the capital base, which often triggers MRQ reporting thresholds or is filed alongside them. Since it is a specific, recurring regulatory disclosure about the capital base, and not a general announcement of a transaction (POS) or a broad financing event (CAP), MRQ is the most appropriate classification for this specific type of capital structure disclosure.
2024-12-04 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is a press release dated November 26, 2024, issued by Mauna Kea Technologies regarding pancreatic cancer awareness and highlighting their Cellvizio® technology. It contains forward-looking statements and references to investor relations contacts and the filing of their 2023 Annual Report with the AMF. This type of announcement, focusing on a specific event (awareness month) and providing company updates/context outside of mandatory periodic financial filings (like 10-K or IR), is typically classified as a general regulatory announcement or press release. Since it is not a formal financial report (10-K, IR, MRQ), an earnings release (ER), a proxy statement (DEF 14A), or a specific transaction notice (DIV, CAP, POS), the most appropriate general category for a corporate communication of this nature is Regulatory Filings (RNS), which serves as a broad category for non-standard regulatory announcements.
2024-11-26 French
Inside Information / Other news releases
Environmental & Social Information Classification · 99% confidence The document is a press release dated November 26, 2024, focusing on Pancreatic Cancer Awareness Month and highlighting the company's product, Cellvizio. It contains forward-looking statements and references the company's 2023 Annual Report filed with the AMF. This type of announcement, which disseminates timely, non-periodic business or awareness information via a press release format, does not fit the specific definitions for 10-K, ER, IR, or DIV. Since it is a general corporate announcement that doesn't fit the more specific categories (like M&A, Capital Change, or Director Dealing), it falls best under the general Regulatory Filings category (RNS), which serves as a fallback for miscellaneous regulatory announcements or press releases.
2024-11-26 English
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is a press release dated November 20, 2024, announcing the termination of a liquidity contract ('contrat de liquidité') between MAUNA KEA TECHNOLOGIES and GILBERT DUPONT. It details the assets remaining in the liquidity account upon termination and compares them to previous balances. This action relates to the management of the company's share capital or market support mechanisms, specifically the termination of a market-making or liquidity provision agreement. This type of announcement, which details a change in capital structure management or a specific financial arrangement outside of standard periodic reporting (like 10-K or IR), fits best under 'Capital/Financing Update' (CAP) or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure without a better fit. Since it directly concerns the management of shares/cash related to market liquidity, 'CAP' is the most specific fit among the provided options, as it relates to capital structure management, even if indirectly. It is not an earnings release (ER), a dividend notice (DIV), or a director's dealing (DIRS). Given the context of ending a liquidity contract, 'CAP' (Capital/Financing Update) is the most appropriate classification.
2024-11-20 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated November 20, 2024, announcing a milestone achieved by a hospital using the company's technology (Cellvizio®). It contains quotes from the CEO and a director, and includes standard 'About' and 'Disclaimer' sections typical of corporate news releases. This type of announcement, which communicates positive operational or business news rather than mandatory financial filings (like 10-K, IR, or ER), is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but given the format, RNS is the most appropriate general category for non-standard announcements. It is not a formal financial report, earnings release, or management discussion.
2024-11-20 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.